RT Journal Article
T1 Self-assembled peptide/polymer hybrid nanoplatform for cancer immunostimulating therapies
A1 Khazaei, Saeedeh
A1 Varela Calviño, Rubén
A1 Rad Malekshahi, Mazda
A1 Quattrini, Federico
A1 Jokar, Safura
A1 Rezaei, Nima
A1 Balalaie, Saeed
A1 Haririan, Ismaeil
A1 Csaba, Noemi Stefania
A1 García Fuentes, Marcos
K1 Cancer vaccine
K1 Self-assembling peptide
K1 Nanovaccines
K1 Hybrid nanoparticles
K1 MAGE-A3
AB Integrating peptide epitopes in self-assembling materials is a successful strategy to obtain nanovaccines with high antigen density and improved efficacy. In this study, self-assembling peptides containing MAGE-A3/PADRE epitopes were designed to generate functional therapeutic nanovaccines. To achieve higher stability, peptide/polymer hybrid nanoparticles were formulated by controlled self-assembly of the engineered peptides. The nanoparticles showed good biocompatibility to both human red blood- and dendritic cells. Incubation of the nanoparticles with immature dendritic cells triggered immune effects that ultimately activated CD8 + cells. The antigen-specific and IgG antibody responses of healthy C57BL/6 mice vaccinated with the nanoparticles were analyzed. The in vivo results indicate a specific response to the nanovaccines, mainly mediated through a cellular pathway. This research indicates that the immunogenicity of peptide epitope vaccines can be effectively enhanced by developing self-assembled peptide-polymer hybrid nanostructures
PB Springer
SN 2190-393X
YR 2023
FD 2023
LK http://hdl.handle.net/10347/33089
UL http://hdl.handle.net/10347/33089
LA eng
NO Khazaei, S., Varela-Calviño, R., Rad-Malekshahi, M. et al. Self-assembled peptide/polymer hybrid nanoplatform for cancer immunostimulating therapies. Drug Deliv. and Transl. Res. 14, 455–473 (2024). https://doi.org/10.1007/s13346-023-01410-y
NO Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by Ministerio de Ciencia e Innovación – Agencia Estatal de Investigación and European Regional Development Fund (ERDF), Ref. PID2021-124986OB-I00 (Project “IMMMA”), and Instituto de Salud Carlos III (ISCIII)/ AC21_2/00046 (Project “RAIN”)/Financiado por la Unión Europea – NextGenerationEU/EURONANOMED 3. This research was a part of a Ph.D. thesis and supported by Tehran University of Medical Sciences, Tehran, Iran [grant no. 35632]
DS Minerva
RD 27 abr 2026